215 related articles for article (PubMed ID: 34707369)
1. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
Gu R; Shi Z; Duan T; Song M
Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
[TBL] [Abstract][Full Text] [Related]
3. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract][Full Text] [Related]
4. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.
Wang LM; Zhao P; Sun XQ; Yan F; Guo Q
World J Clin Cases; 2023 Aug; 11(22):5322-5328. PubMed ID: 37621597
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.
Shi L; Gao S; Tong L; Meng Q; Zhou S; Yu D; Dong Y; Liu Z
Front Oncol; 2023; 13():1120511. PubMed ID: 37409244
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer.
Hu Y; Ren S; Wang R; Han W; Xiao P; Wang L; Yu F; Liu W
Front Pharmacol; 2022; 13():816683. PubMed ID: 35873553
[No Abstract] [Full Text] [Related]
7. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
[TBL] [Abstract][Full Text] [Related]
8. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
9. Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy.
Cao P; Zhao Q; Li Y; Shi R; Zhu G; Zhang Z; Zhang H; Liu M; Wei S; Liu H; Chen J
Front Pharmacol; 2023; 14():1140894. PubMed ID: 37663243
[TBL] [Abstract][Full Text] [Related]
10. Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.
Yue P; Zhang S; Zhou L; Xiang J; Zhao S; Chen X; Dong L; Yang W; Xiang Y
Transl Cancer Res; 2021 Aug; 10(8):3856-3863. PubMed ID: 35116684
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (
Li J; Huang K; Ji H; Qian J; Lu H; Zhang Y; Russo A; Romero A; Urbanska EM; Tabbò F; Zhao X; Chu T
Transl Lung Cancer Res; 2023 Dec; 12(12):2505-2519. PubMed ID: 38205204
[TBL] [Abstract][Full Text] [Related]
12. ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report.
Takayasu H; Kata Y; Otsu Y; Inoue S; Kaneko T
Cureus; 2023 Mar; 15(3):e36711. PubMed ID: 37113357
[TBL] [Abstract][Full Text] [Related]
13. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.
Imanishi N; Yoneda K; Taira A; Ichiki Y; Sato N; Hisaoka M; Tanaka F
Surg Case Rep; 2018 Mar; 4(1):19. PubMed ID: 29524063
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare
Li Y; Duan P; Guan Y; Chen Q; Grenda A; Christopoulos P; Denis MG; Guo Q
Transl Lung Cancer Res; 2022 Jan; 11(1):100-110. PubMed ID: 35242631
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
16. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
17.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
18. Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC.
Hashimoto H; Komori K; Kameda K; Taguchi S; Ozeki Y
Surg Case Rep; 2022 Apr; 8(1):59. PubMed ID: 35366157
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase fusion protein expression is associated with a favorable prognosis in resected invasive mucinous lung adenocarcinoma: A retrospective study from two Chinese tertiary hospitals.
Wang J; Wei P; Liu J; Su P; Xing A; Jing H; Hao J
J Cancer Res Ther; 2022 Apr; 18(2):445-451. PubMed ID: 35645113
[TBL] [Abstract][Full Text] [Related]
20. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
